Moderna Inc. has published a document detailing interim data from a Phase 1/2 study evaluating the safety and pharmacology of mRNA-3705 in participants with MUT-deficient Methylmalonic Acidemia. The study focuses on weight-based intravenous dosing administered every two or three weeks for up to ten doses. The document provides information on the study's design, objectives, and dosing regimens. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.